Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Cash & Equivalents (2016 - 2025)

Marimed (MRMD) has disclosed Cash & Equivalents for 15 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 22.0% to $8.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.9 million through Dec 2025, up 22.0% year-over-year, with the annual reading at $8.9 million for FY2025, 22.0% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $8.9 million at Marimed, up from $6.6 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $33.5 million in Q1 2022, with the low at $6.1 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $14.1 million, with a median of $11.7 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents skyrocketed 1031.22% in 2021, then plummeted 67.2% in 2022.
  • Over 5 years, Cash & Equivalents stood at $29.7 million in 2021, then tumbled by 67.2% to $9.7 million in 2022, then surged by 50.41% to $14.6 million in 2023, then tumbled by 50.28% to $7.3 million in 2024, then grew by 22.0% to $8.9 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $8.9 million, $6.6 million, and $6.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.